FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978715268> ?p ?o ?g. }

• W1978715268 endingPage "33" @default.
• W1978715268 startingPage "33" @default.
• W1978715268 abstract "Although androgen deprivation therapy (ADT) has been used for more than half a century to treat prostate cancer, its mechanism and associated side effects are continuously updated. Androgens are key players in glucose homeostasis and lipid metabolism. In fact, lower total testosterone predicts a higher incidence of the metabolic syndrome, a cluster of risk factors predisposing patients to late onset diabetes mellitus, atherosclerosis and cardiovascular (CVS) morbidity and mortality.1 Since CVS disease is the most common competing cause for mortality, we should make all efforts to minimize our iatrogenic contribution to the metabolic syndrome and familiarize ourselves with the growing body of evidence linking ADT to the metabolic syndrome.2,3 Mohamedali and colleagues present their experience with the impact of long-term ADT on blood glucose levels in non-diabetic prostate cancer patients. The authors demonstrated that 1 year of ADT use is associated with elevated fasting glucose levels.4 This data is in line with a recent review of the ADT/metabolic syndrome which showed a clear casual association between ADT and diabetes mellitus, but the causal association is not as strong with CVS morbidity.5 The link needs to be better explored as novel ADT strategies are about to change our practice. In recent years it has become clear that current modes of castration are far from optimal in achieving complete androgen deprivation in prostate cancer cells. Multiple pre-clinical evidences suggest that prostate cancer cells can produce androgens which activate the androgen receptor already in concentrations lower than those traditionally defined as castrated serum testosterone levels (<20 ng/dL). Accordingly, although not completely validated, clinical observations suggest the lower the testosterone level under ADT, the longer the survival;6 it is possible that even lower levels of testosterone within and it is possible that even transient events of testosterone break through within the framework of ADT can accelerate disease progression.7 Hence, the current trend in ADT is a more strict deprivation of androgens in castrate resistant prostate cancer, and what we used to define as maximal androgen blocked (MAB) will certainly be expanded with the introduction of novel products, such as arbiraterone and MDV3100. It is reasonable to expect that novel therapeutic strategies that induce more effective testosterone suppression will reciprocally accentuate the metabolic side effect profile of ADT. Data comparing the long-term metabolic side effect of different modes of castration is currently limited,8 but once available, should better guide us in treating patients with known risk factors for CVS disease. We should incorporate routine baseline and follow-up assessments of metabolic measurements (fasting glucose levels, lipids, BMI) and advocate lifestyle modification for our ADT patients. We should also stay tuned for potentially more detrimental metabolic side effects with more strict MAB regimens." @default.
• W1978715268 created "2016-06-24" @default.
• W1978715268 creator A5000779166 @default.
• W1978715268 date "2011-02-01" @default.
• W1978715268 modified "2023-09-25" @default.
• W1978715268 title "ADT and the metabolic syndrome: no good deed goes unpunished" @default.
• W1978715268 cites W131662603 @default.
• W1978715268 cites W1969259971 @default.
• W1978715268 cites W2032318058 @default.
• W1978715268 cites W2089971024 @default.
• W1978715268 cites W2119283349 @default.
• W1978715268 cites W2135481568 @default.
• W1978715268 cites W2138323789 @default.
• W1978715268 cites W2159437944 @default.
• W1978715268 doi "https://doi.org/10.5489/cuaj.11017" @default.
• W1978715268 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3036753" @default.
• W1978715268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21470510" @default.
• W1978715268 hasPublicationYear "2011" @default.
• W1978715268 type Work @default.
• W1978715268 sameAs 1978715268 @default.
• W1978715268 citedByCount "1" @default.
• W1978715268 crossrefType "journal-article" @default.
• W1978715268 hasAuthorship W1978715268A5000779166 @default.
• W1978715268 hasBestOaLocation W19787152682 @default.
• W1978715268 hasConcept C138885662 @default.
• W1978715268 hasConcept C144024400 @default.
• W1978715268 hasConcept C17744445 @default.
• W1978715268 hasConcept C190253527 @default.
• W1978715268 hasConcept C199539241 @default.
• W1978715268 hasConcept C2779845782 @default.
• W1978715268 hasConceptScore W1978715268C138885662 @default.
• W1978715268 hasConceptScore W1978715268C144024400 @default.
• W1978715268 hasConceptScore W1978715268C17744445 @default.
• W1978715268 hasConceptScore W1978715268C190253527 @default.
• W1978715268 hasConceptScore W1978715268C199539241 @default.
• W1978715268 hasConceptScore W1978715268C2779845782 @default.
• W1978715268 hasLocation W19787152681 @default.
• W1978715268 hasLocation W19787152682 @default.
• W1978715268 hasLocation W19787152683 @default.
• W1978715268 hasLocation W19787152684 @default.
• W1978715268 hasOpenAccess W1978715268 @default.
• W1978715268 hasPrimaryLocation W19787152681 @default.
• W1978715268 hasRelatedWork W11443222 @default.
• W1978715268 hasRelatedWork W1561372878 @default.
• W1978715268 hasRelatedWork W1810090705 @default.
• W1978715268 hasRelatedWork W2161249805 @default.
• W1978715268 hasRelatedWork W2475804252 @default.
• W1978715268 hasRelatedWork W2748952813 @default.
• W1978715268 hasRelatedWork W2899084033 @default.
• W1978715268 hasRelatedWork W4242017234 @default.
• W1978715268 hasRelatedWork W4386335272 @default.
• W1978715268 hasRelatedWork W3126029117 @default.
• W1978715268 isParatext "false" @default.
• W1978715268 isRetracted "false" @default.
• W1978715268 magId "1978715268" @default.
• W1978715268 workType "article" @default.